@dra.suelimiranda's TRT claims need more context

What did @dra.suelimiranda actually say?

Honestly, it's not clear. The transcript is incoherent, a looping, fragmented sentence that never resolves into an actual claim. There is no identifiable medical assertion, no testosterone-related statement, and no health advice that can be quoted or evaluated in any meaningful way.

The video is tagged with hashtags including emagrecimento (weight loss), cancer, imunidade (immunity), and testosterone, which suggests the creator intended to discuss TRT or hormone optimization. But the spoken content, as transcribed, does not deliver any of that. What we have is a series of recursive, unfinished phrases: "it's not going to be going to be going to be." That is not a medical claim. It is not anything reviewable.

This matters because the hashtag framing, pairing testosterone with cancer and immunity, can prime viewers to receive health information that may or may not be accurate. The video's context signals authority even when the content does not.

Does the science back this up?

There is nothing in the transcript to test against the science. However, given the hashtags, it's worth briefly addressing what the evidence actually says about TRT, cancer, and immunity, since those appear to be the intended themes.

The relationship between testosterone and cancer is genuinely complicated. For prostate cancer specifically, the old "fuel on the fire" model, based on Huggins and Hodges (1941), has been substantially revised. Morgentaler and Traish (2009, European Urology) proposed the saturation model, arguing that prostate tissue has a finite androgen receptor capacity and that supraphysiologic testosterone does not proportionally increase cancer risk. That said, testosterone is still contraindicated in men with active or suspected prostate cancer, per Endocrine Society clinical guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism).

On immunity, testosterone has immunomodulatory effects, generally considered mildly immunosuppressive at high levels (Ding et al., 2015, Frontiers in Immunology). Connecting TRT to immune enhancement is a stretch without qualifying context.

What did they get wrong (or right)?

There is no evaluable claim here, so a standard accuracy verdict is not possible. That itself is the problem worth naming.

What the video gets wrong, structurally, is using high-stakes hashtags like cancer alongside hormone therapy content in a way that implies an informational relationship that the content never actually establishes. Viewers searching those terms may land on a video that signals expertise but delivers nothing substantive. That is a form of misleading framing even if no false claim was technically made.

To be fair, it is possible the transcript represents a technical error, a corrupted audio capture, or a video that was primarily visual with text overlays not captured here. If that is the case, the video cannot be fairly evaluated on transcript alone. But based solely on what was said, there is no correct or incorrect medical claim to credit or correct.

What should you actually know?

If you found this video while researching TRT, here is what the evidence actually supports. Testosterone replacement therapy is an established treatment for clinically diagnosed hypogonadism, defined by consistently low serum testosterone plus symptoms, not just one number on a lab panel. Diagnosis requires two morning fasting measurements below the lab reference range, per Bhasin et al. (2018).

TRT is not a weight loss treatment on its own. Some studies show modest improvements in body composition in hypogonadal men, but it is not approved or indicated solely for fat loss. The emagrecimento hashtag here overstates that connection.

Anyone pairing TRT content with cancer claims should be held to a high evidentiary standard. Testosterone does not cure cancer. It is not an immune booster in any clinically established sense. If a creator is implying otherwise, that deserves direct skepticism regardless of their credentials.